Phase 3 N=60 Pilot Study on the Efficacy of Pascoflair in an Acute Stressful Situation (TSST)
Healthy · Stress
Primary: VAS Insecurity (During) — 56.87; 60.93 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=544 Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
Chronic Obstructive Pulmonary Disease
Primary: Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1) — -0.008; 0.043; 0.064 L — p=0.019
Phase 3 N=21,162 Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Myocardial Infarction · Cardiovascular Death · Atherothrombosis
Primary: Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From…
Phase 3 N=334 Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
Pain · Low Back Pain
Primary: Change in Pain Intensity From Baseline to Week 12 — 0.33; 0.46 units on a scale — p=.5870
Phase 3 N=2,333 Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
Influenza
Primary: Geometric Mean Titre (GMT) in Subjects After Receiving One or Two Doses of Either QIVc, TIV1c or TIV2c — 96; 100; NA; 1090 Titers
Phase 3 N=107 Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
Seasonal Allergic Rhinitis
Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Treatment of Phleum Pratense Specific Immunoglobulin G4 (IgG4) in Serum — 0.684; 0.050 mgA/L
Phase 3 N=458 Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
Intraabdominal Infections
Primary: Number of Subjects With Adverse Events — 175; 82; 20; 6 Subjects
Phase 3 N=376 Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Hypertension
Primary: Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP) — -4.26; -1.04 mmHg — p=<0.001
Phase 3 N=437 Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
Opioid-Induced Bowel Dysfunction
Primary: Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8 — 2.4; 2.6 Spontaneous Bowel…
Phase 3 N=9 Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
Epilepsy · Partial-onset Seizures
Primary: The Total Number of Subjects Experiencing at Least One Adverse Event During the Study — 4 participants
Phase 3 N=1,301 A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years
Healthy Japanese Children Age 7 Years Through 18 Years
Primary: the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain) — 0; 1 Participants
Phase 3 N=273 A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Human Immunodeficiency Virus (HIV) Infections · Acquired Immunodeficiency Syndrome (AIDS) Virus
Primary: Virologic Response (Food Drug and Administration [FDA] Snapshot, Switch = Failure) — 87.0; 95.0 Percentage of Participants — p=0.2331
Phase 3 N=350 A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Non-myeloid Malignancies · Chemotherapy Induced Anaemia
Primary: Change in Hb Concentration — 0.48; 0.44 g/dL
Phase 3 N=295 Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 28 in Quality of Life Scale (QLS) Total Score — 7.47; 2.80 units on a scale — p=0.036
Phase 3 N=351 Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia
Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. — 0.57; 0.35 g/dL